Genspeed Biotech is the latest addition to the EOSS Group. The highly innovative Upper Austrian start-up has a diagnostic technology acquired from medical technology group Greiner Bio-One, which is fully in line with the global trend towards rapid disease detection.
EOSS founded the company at the end of 2016 together with former Greiner Bio-One managers Dr. Max Sonnleitner and Dr. Sonja Kierstein, and in the process acquired patents and assets from the Upper Austrian medical technology group. With now ten employees, the start-up continues to develop the patented technology, which is a highly scalable platform for rapid tests on DNA, RNA and protein basis. To date, rapid tests for multi-resistant hospital germs and periodontitis have been implemented on the platform, which are produced and distributed by the team. The technology is based on microfluidic biochips, miniaturized optical detection and automation and enables in vitro certified rapid tests for qualitative and quantitative analysis of DNA, RNA and proteins. Eliminating long hands-on times massively shortens the time to treatment initiation and prevents the administration of incorrect drugs.